About Axovant Sciences (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708
Debt
Debt-to-Equity Ratio0.45%
Current Ratio4.58%
Quick Ratio4.58%
Price-To-Earnings
Trailing P/E Ratio-0.59
Forward P/E Ratio-0.49
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book0.86
Profitability
EPS (Most Recent Fiscal Year)($1.82)
Net Income$-180,950,000.00
Net MarginsN/A
Return on Equity-168.63%
Return on Assets-102.29%
Miscellaneous
Employees69
Outstanding Shares107,790,000
Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions
What is Axovant Sciences' stock symbol?
Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."
How were Axovant Sciences' earnings last quarter?
Axovant Sciences (NASDAQ:AXON) issued its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.12. View Axovant Sciences' Earnings History.
When is Axovant Sciences' next earnings date?
What price target have analysts set for AXON?
11 equities research analysts have issued 12 month target prices for Axovant Sciences' stock. Their predictions range from $2.50 to $30.00. On average, they anticipate Axovant Sciences' stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Axovant Sciences.
What are Wall Street analysts saying about Axovant Sciences stock?
Here are some recent quotes from research analysts about Axovant Sciences stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/14/2018)
- 2. Cowen Inc analysts commented, "We maintain our BUY rating and $25 PT for SVRA shares." (2/13/2018)
- 3. HC Wainwright analysts commented, "We hosted a conference call with a medical physicist on October 17, 2017. The consultant highlighted a number of key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC as well as main differences between ViewRay’s low-T MRIdian technology and competitor Elekta’s yet-to-be approved High- T Unity system. Replay information available upon request. KeyPoints High-T vs. Low-T. While in the context of a diagnosis, a high-T system would surely lead to greater image resolution, the low-T system appears more suitable in the treatment phase where the key lies in the ability to locate the patient’s tumor in a dynamic way. Image quality, it turns out, can be improved through various techniques according to our consultant." (10/19/2017)
Who are some of Axovant Sciences' key competitors?
Some companies that are related to Axovant Sciences include Chimerix (CMRX), MannKind (MNKD), Neos Therapeutics (NEOS), Molecular Templates (MTEM), Melinta Therapeutics (MLNT), Ardelyx (ARDX), Viking Therapeutics (VKTX), Calithera Biosciences (CALA), Synlogic (SYBX), Aratana Therapeutics (PETX), CTI BioPharma (CTIC), Corvus Pharmaceuticals (CRVS), Recro Pharma (REPH), Fortress Biotech (FBIO), Verona Pharma (VRNA), Tyme Technologies (TYME), VBI Vaccines (VBIV) and Verastem (VSTM).
Who are Axovant Sciences' key executives?
Axovant Sciences' management team includes the folowing people:
- Dr. Gregory M. Weinhoff, Chief Financial Officer (Age 47)
- Dr. Pavan Cheruvu, Chief Exec. Officer
- Mr. Michael Adasczik, Principal Accounting Officer (Age 44)
- Mr. Jonathan Neely, Head of Investor Relations & Corp. Communications
- Ms. Marianne L. Romeo Dinsmore, Head of Global Transactions & Risk Management (Age 50)
When did Axovant Sciences IPO?
(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Has Axovant Sciences been receiving favorable news coverage?
News coverage about AXON stock has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axovant Sciences earned a coverage optimism score of 0.14 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.98 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Axovant Sciences?
Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axovant Sciences' stock price today?
One share of AXON stock can currently be purchased for approximately $1.08.
How big of a company is Axovant Sciences?
Axovant Sciences has a market capitalization of $120.72 million. The biotechnology company earns $-180,950,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Axovant Sciences employs 69 workers across the globe.
How can I contact Axovant Sciences?
Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.
MarketBeat Community Rating for Axovant Sciences (AXON)
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
Axovant Sciences (NASDAQ:AXON) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Axovant Sciences in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 1,265.74%. The high price target for AXON is $30.00 and the low price target for AXON is $2.50. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.36 | 2.36 | 2.36 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.75 | $14.75 | $14.6818 |
| Price Target Upside: | 1,265.74% upside | 714.92% upside | 549.78% upside | 149.69% upside |
Axovant Sciences (NASDAQ:AXON) Consensus Price Target History
Axovant Sciences (NASDAQ:AXON) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Axovant Sciences (NASDAQ:AXON) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Axovant Sciences (NASDAQ AXON) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 72.40%
Institutional Ownership Percentage: 93.03%
Axovant Sciences (NASDAQ AXON) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/27/2018 | George Bickerstaff | Director | Buy | 25,000 | $1.50 | $37,500.00 | |  |
| 4/17/2017 | David Hung | Insider | Buy | 539,375 | $18.54 | $10,000,012.50 | 539,375 | |
| 4/17/2017 | W Anthony Vernon | Director | Buy | 53,937 | $18.54 | $999,991.98 | 53,937 | |
| 3/10/2016 | Mark Altmeyer | Insider | Buy | 2,300 | $11.14 | $25,622.00 | 2,300 | |
(Data available from 1/1/2013 forward)
Axovant Sciences (NASDAQ AXON) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Axovant Sciences (AXON) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 2:21 PM |
| Axovant Sciences (AXON) Lifted to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 4:55 PM |
| Axovant Sciences Ltd (AXON) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 8:48 AM |
| Zacks: Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.39 EPS
www.americanbankingnews.com - April 9 at 7:19 PM |
| BidaskClub Downgrades Axovant Sciences (AXON) to Sell
www.americanbankingnews.com - April 7 at 10:55 AM |
| ValuEngine Lowers Axovant Sciences (AXON) to Strong Sell
www.americanbankingnews.com - April 3 at 6:58 PM |
| Axovant Sciences (AXON) Earns Hold Rating from Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM |
| Axovant Sciences (AXON) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM |
| Chardan Capital Upgrades Axovant Sciences (AXON) to "Neutral"
www.americanbankingnews.com - March 29 at 5:16 PM |
| Axovant Sciences (AXON) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 8:44 PM |
| Analysts Expect Axovant Sciences Ltd (AXON) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - March 23 at 7:26 PM |
 | Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant
finance.yahoo.com - March 23 at 9:07 AM |
| Axovant Sciences Ltd (AXON) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 17 at 9:04 AM |
| Hudson Bay Capital Management LP Purchases New Position in Axovant Sciences Ltd (AXON)
www.americanbankingnews.com - March 2 at 12:49 PM |
| Insider Buying: Axovant Sciences Ltd (AXON) Director Buys 25,000 Shares of Stock
www.americanbankingnews.com - March 1 at 10:44 PM |
| Axovant Sciences (AXON) PT Raised to $37.00
www.americanbankingnews.com - February 28 at 7:24 PM |
| Axovant Sciences' (AXON) "Hold" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - February 18 at 10:22 PM |
| Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.48 EPS
www.americanbankingnews.com - February 17 at 9:08 PM |
| FY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by Analyst
www.americanbankingnews.com - February 15 at 11:40 AM |
| Axovant Sciences (AXON) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 14 at 6:00 PM |
 | AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences ... - Business Wire (press release)
www.businesswire.com - February 14 at 3:16 PM |
| AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors
finance.yahoo.com - February 14 at 3:16 PM |
| Axovant Sciences Ltd to Post FY2018 Earnings of ($2.10) Per Share, Jefferies Group Forecasts (AXON)
www.americanbankingnews.com - February 14 at 11:38 AM |
 | Is This the End of Axovant?
www.msn.com - February 14 at 5:22 AM |
| Axovant Sciences (AXON) Rating Reiterated by Cowen
www.americanbankingnews.com - February 13 at 8:08 PM |
 | Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD ... - Nasdaq
www.nasdaq.com - February 13 at 5:25 AM |
| Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD,AVEO - Nasdaq
www.nasdaq.com - February 12 at 3:15 PM |
 | Axovant Stock Tumbles After Sweeping Leadership Changes - Wall Street Journal
www.wsj.com - February 12 at 3:15 PM |
 | Axovant shares slide 21% premarket on news of CEO, COO departures - MarketWatch
www.marketwatch.com - February 12 at 3:15 PM |
| Axovant Shares Crater as CEO and President Both Resign
finance.yahoo.com - February 12 at 3:15 PM |
| Axovant Sciences CEO David Hung resigns, shares tumble
finance.yahoo.com - February 12 at 3:15 PM |
| [$$] Axovant Stock Tumbles After Sweeping Leadership Changes
finance.yahoo.com - February 12 at 3:15 PM |
| Axovant shares slide 21% premarket on news of CEO, COO departures
finance.yahoo.com - February 12 at 3:15 PM |
| Zacks: Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - January 31 at 11:10 PM |
| Axovant Sciences (AXON) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 31 at 7:18 PM |
 | This Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen - PR Newswire (press release)
www.prnewswire.com - January 31 at 3:15 PM |
| Axovant Sciences Ltd (AXON) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 26 at 8:44 AM |
| Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - January 15 at 1:10 AM |
| CBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall - Nasdaq
www.nasdaq.com - January 12 at 3:38 PM |
| Axovant Sciences (AXON) Rating Lowered to Market Perform at Cowen
www.americanbankingnews.com - January 12 at 8:02 AM |
| After A Freefall In Axovant Shares, Chardan Upgrades
finance.yahoo.com - January 10 at 3:41 PM |
| Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
finance.yahoo.com - January 10 at 11:22 AM |
 | Here's Why Axovant Sciences Dropped Today
www.fool.com - January 9 at 11:08 AM |
| GoPro, Axovant Sciences Plunge into Monday’s 52-Week Low Club
www.marketwatch.com - January 9 at 11:08 AM |
| CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
finance.yahoo.com - January 9 at 11:08 AM |
 | 38 Stocks Moving In Monday's Mid-Day Session - Benzinga
www.benzinga.com - January 8 at 3:46 PM |
| Axovant Will No Longer Develop Lead Dementia Drug - Wall Street Journal
www.wsj.com - January 8 at 3:46 PM |
| Axovant Crumbles Following Alzheimer’s Study Update
finance.yahoo.com - January 8 at 3:46 PM |
| [$$] Axovant Will No Longer Develop Lead Dementia Drug
finance.yahoo.com - January 8 at 3:46 PM |
| Here's Why Axovant Sciences Dropped Today
finance.yahoo.com - January 8 at 3:46 PM |
Axovant Sciences (NASDAQ:AXON) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Axovant Sciences (NASDAQ:AXON) Income Statement, Balance Sheet and Cash Flow Statement
Axovant Sciences (NASDAQ AXON) Stock Chart for Saturday, April, 21, 2018
Loading chart…
